zoledronic acid has been researched along with Cancer of Ovary in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Dell'Endice, S; Göbel, A; Jaschke, N; Kuhlmann, JD; Rachner, TD; Wimberger, P; Zinna, VM | 1 |
| Abdullah, MI; Abed, MN; Richardson, A | 1 |
| Cabillic, F; Catros, V; Daniel, P; Dessarthe, B; Henno, S; Jaffre, I; Lavoué, V; Levêque, J; Thedrez, A | 1 |
| Aslan, B; Calin, G; Dalton, HJ; Del C Monroig, P; Fernandez-de Thomas, RJ; Fuentes-Mattei, E; Gonzalez-Villasana, V; Ivan, C; Kahraman, N; Kanlikilicer, P; Lopez-Berestein, G; Ozpolat, B; Pradeep, S; Previs, RA; Rodriguez-Aguayo, C; Sood, AK; Velazquez-Torres, G; Wang, H | 1 |
| Alberts, DS; Greene, MH; Hibler, EA; Kauderer, J; Rodriguez, GC | 1 |
| Cree, IA; Dexel, S; Fernando, A; Glaysher, S; Knight, LA; Kurbacher, CM; Reichelt, R; Reinhold, U | 1 |
| Atmaca, H; Cirak, Y; Degirmenci, M; Gorumlu, G; Karabulut, B; Karaca, B; Purcu, DU; Sanli, UA; Tunali, D; Uslu, R; Uzunoglu, S | 1 |
| Atmaca, H; Cakar, B; Karabulut, B; Karaca, B; Kisim, A; Muslu, U; Uslu, R; Uzunoglu, S; Varol, U | 1 |
| Fehm, T; Kootz, B; Neubauer, H; Schott, S; Seeger, H; Wallwiener, M | 1 |
| Cannon, MJ; Goyne, H; Stone, PJ | 1 |
| Bansard, JY; Bauville, E; Bouet-Toussaint, F; Burtin, F; Cabillic, F; Catros, V; Daniel, P; de La Pintière, CT; Dessarthe, B; Foucher, F; Henno, S; Lavoué, V; Levêque, J; Thedrez, A; Toutirais, O | 1 |
| Conroy, M; Cree, IA; Fernando, A; Knight, LA; Kurbacher, CM; Polak, M | 1 |
1 trial(s) available for zoledronic acid and Cancer of Ovary
| Article | Year |
|---|---|
Bone loss after oophorectomy among high-risk women: an NRG oncology/gynecologic oncology group study.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteoporosis; Ovarian Neoplasms; Ovariectomy; Premenopause; Risk Factors; Zoledronic Acid | 2016 |
11 other study(ies) available for zoledronic acid and Cancer of Ovary
| Article | Year |
|---|---|
Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer.
Topics: Apoptosis; Atorvastatin; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Interleukin-8; Mevalonic Acid; Ovarian Neoplasms; Polyisoprenyl Phosphates; Prenylation; Rosuvastatin Calcium; Sesquiterpenes; Simvastatin; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2020 |
Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Diterpenes; Female; Geranyltranstransferase; GTP Phosphohydrolases; Humans; Imidazoles; Leucine; Mevalonic Acid; Naphthalenes; Ovarian Neoplasms; Quinolines; Zoledronic Acid | 2017 |
A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; CD3 Complex; Cell Proliferation; Cells, Cultured; Combined Modality Therapy; Diphosphates; Diphosphonates; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Imidazoles; Interferon-gamma; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prognosis; Survival Analysis; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Treatment Outcome; Tumor Necrosis Factor-alpha; Zoledronic Acid | 2013 |
Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer.
Topics: Albumins; Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Diphosphonates; Female; High-Throughput Screening Assays; Humans; Imidazoles; Immunohistochemistry; Matrix Metalloproteinase 2; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; p21-Activated Kinases; p38 Mitogen-Activated Protein Kinases; Paclitaxel; rac1 GTP-Binding Protein; Signal Transduction; Transfection; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diphosphonates; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Imidazoles; Indoles; Mevalonic Acid; Middle Aged; Ovarian Neoplasms; Signal Transduction; Tumor Cells, Cultured; Zoledronic Acid | 2009 |
Combined gossypol and zoledronic acid treatment results in synergistic induction of cell death and regulates angiogenic molecules in ovarian cancer cells.
Topics: Angiogenesis Inducing Agents; Caspase 3; Caspase 7; Cell Death; Cell Line, Tumor; Cell Proliferation; Diphosphonates; DNA Fragmentation; Down-Regulation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Gossypol; Humans; Imidazoles; Ovarian Neoplasms; RNA, Messenger; Zoledronic Acid | 2009 |
Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Diphosphonates; Drug Synergism; Female; Gene Expression Profiling; Humans; Imidazoles; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tretinoin; Tumor Cells, Cultured; Zoledronic Acid | 2010 |
Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Alendronate; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Imidazoles; Inhibitory Concentration 50; Ovarian Neoplasms; Reference Standards; Zoledronic Acid | 2012 |
Combinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Agents, Alkylating; B7-H1 Antigen; Cancer Vaccines; Clonal Anergy; Cyclophosphamide; Dendritic Cells; Diphosphonates; Female; Humans; Imidazoles; Immunosuppression Therapy; Immunotherapy, Active; Indoleamine-Pyrrole 2,3,-Dioxygenase; Macrophages; Neoplasms; Ovarian Neoplasms; Pamidronate; T-Lymphocytes, Regulatory; Th17 Cells; V-Set Domain-Containing T-Cell Activation Inhibitor 1; Zoledronic Acid | 2011 |
Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Ascites; Cell Line, Tumor; Dinoprostone; Diphosphonates; Female; Flow Cytometry; Humans; Imidazoles; Immunotherapy; Middle Aged; Ovarian Neoplasms; T-Lymphocytes, Cytotoxic; Zoledronic Acid | 2012 |
Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Alendronate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caspase 3; Caspase 7; Caspases; Cell Line, Tumor; Cell Survival; Cisplatin; Clodronic Acid; Diphosphonates; Energy Metabolism; Female; Humans; Imidazoles; Inhibitory Concentration 50; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured; Zoledronic Acid | 2005 |